Characteristics of relapsed/refractory diffuse large B‐cell lymphoma patients with durable responses to maveropepimut‐S, pembrolizumab, and cyclophosphamide: Long‐term follow‐up from the SPiReL trial

20242 citationsJournal Articlediamond Open Access

Authors

Arjun Pandey · Sunnybrook Health Science Centre

Kim Roos · Sunnybrook Hospital

Yidi Jiang · Sunnybrook Hospital

Kathryn Mangoff · Sunnybrook Hospital

Gail Klein · Sunnybrook Hospital

Nick Forward · Queen Elizabeth II Health Sciences Centre

Douglas A. Stewart ·

Abstract

Combination immunotherapy regimens such as this could offer a promising alternative to other treatments with significant toxicities for select patients.

Topics & Keywords

CAR-T cell therapy research Lymphoma Diagnosis and Treatment Immune Cell Function and Interaction

Publication Details

Published in: eJHaem

Volume 6, Issue 1, pp. e1062-e1062

DOI: 10.1002/jha2.1062

Field-Weighted Citation Impact: 0.58

Command Palette

Characteristics of relapsed/refractory diffuse large B‐cell lymphoma patients with durable responses to maveropepimut‐S, pembrolizumab, and cyclophosphamide: Long‐term follow‐up from the SPiReL trial

Authors

Abstract

Topics & Keywords

Publication Details